Loading clinical trials...

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China | Clinical Trials | Clareo Health

WITHDRAWN

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

NCT05184231•Ipsen

View on ClinicalTrials.gov

Summary

The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For Patients:
•Age 18 years or older
•Diagnosed with acromegaly
•Receiving current SSA injections for acromegaly treatment for at least 3 months
•Signed electronic Informed Consent Form (eICF)
•For Physicians:
•Licensed endocrinologists or neurosurgeons
•Having prescribed SSAs for at least five patients with acromegaly in the past 6 months
•Signed eICF

Exclusion Criteria

•Patients will not be included in the survey if they meet any of the following criteria:
•Patients who are not able to successfully complete the questionnaire independently
•Pregnant patients

Key Dates

Start Date

February 13, 2023

Primary Completion Date

October 1, 2023

Completion Date

October 1, 2023

Last Updated

March 17, 2023

Conditions

Acromegaly

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT00001595

PanhypopituitarismGigantism/Acromegaly+2 more

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

NCT04837040

Acromegaly

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Inclusion Criteria

Exclusion Criteria

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients